2017 Emory Cancer Conference

Meeting Overview

On behalf of Sagar Lonial, MD, and Suresh Ramalingam, MD, course directors, we are pleased to invite you to the 2017 Debates and Didactics in Hematology and Oncology conference, to be held in Sea Island, Georgia, July 26 – 30, 2017.


The 2017 Debates and Didactics in Hematology and Oncology conference will feature a comprehensive review into mechanisms of disease and treatments for patients with cancer or blood disorders. Expert faculty from Winship and thought leaders from across the nation will engage in interactive debates and didactic lectures on controversial topics and standards of care to offer you the opportunity to hear how science supports each point of view. Presentations and discussions will focus on current basic and clinical research, including the use of molecular targeted therapy, immunotherapies, and other novel therapeutic approaches.

Target Audience

This educational activity is intended for hematologists, oncologists, and other allied healthcare professionals interested in the management of hematology and oncology.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer

Fee Information

Registration Fees Before May 15 On or After May 15
Physician/PharmD/PhD $450 $650
Mid-level provider/Nurse $300 $375
Fellows, Residents, Students $25 $40
Pharmaceutical industry representative (non-exhibitor) $800 $1000


For additional information contact Jaye Harden, or 678.892.1353.


Course Directors

  • Sagar Lonial, MD
    Professor and Chair, Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Chief Medical Officer
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

  • Suresh S. Ramalingam, MD
    Professor, Department of Hematology and Medical Oncology
    Roberto C. Goizueta Distinguished Chair for Cancer Research
    Emory University School of Medicine
    Deputy Director
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

Guest Faculty

  • Kenneth Anderson, MD
    Dana-Farber Cancer Institute
    Boston, Massachusetts
  • James Armitage, MD, FASCO
    University of Nebraska Medical Center
    Omaha, Nebraska
  • Michael Atkins, MD
    Georgetown Lombardi Comprehensive Cancer Center
    Washington, DC
  • Hagop Kantarjian, MD
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas
  • Susan O’Brien, MD
    UC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California

Winship Cancer Institute and Emory University Faculty

  • Olatunji Alese, MD
    Assistant Professor, Department of Hematology
    and Medical Oncology
  • Mehrdad Alemozaffar, MD
    Assistant Professor, Department of Urology
  • Olatunji Alese, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Ana Antun, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Martha Arellano, MD
    Associate Professor, Department of Hematology and Medical Oncology
  • Jonathan Beitler, MD, MBA, FACR, FASTRO
    Professor of Radiation Oncology, Otolaryngology, Hematology and Oncology
    Georgia Research Alliance Cancer Scientist
  • Mehmet Bilen, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • William Blum, MD
    Acting Professor, Department of Hematology and Medical Oncology
    Director of the Acute Leukemia Program
  • Bradley Carthon, MD, PhD
    Assistant Professor, Director of Medical Oncology Inpatient
  • Jonathon Cohen, MD, MS
    Assistant Professor, Department of Hematology and Medical Oncology
  • Walter J. Curran, Jr, MD
    Executive Director of Winship Cancer Institute
    Lawrence W. Davis Professor and Chair of Radiation Oncology
    Group Chairman, NRG Oncology
    Georgia Research Alliance Eminent Scholar and Chair in Cancer Research
  • Bassel El-Rayes, MD
    Professor, Department of Hematology and Medical Oncology
    Associate Director for Clinical Research
    Director of Gastrointestinal Oncology Program
  • Christopher Flowers, MD, MS
    Director of the Emory Lymphoma Program
    Associate Professor, Department of Hematology and Medical Oncology
  • Manila Gaddh, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Keerthi Gogineni, MD, MSHP
    Assistant Professor, Department of Hematology and Medical Oncology
  • R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
    Associate Professor, Hematology/Medical Oncology and Pharmacology Emory University School of Medicine
    Director, Phase 1 Clinical Trials Section
  • Leonard T. Heffner, Jr, MD
    Professor, Department of Hematology and Medical Oncology
  • Ira Horowitz, MD, SM, FACOG, FACS
    Chief Medical Officer and Associate Dean, Clinical Services, Emory University Hospital
    John D. Thompson Professor and Chairman, Department of Gynecology and Obstetrics
    Assistant Dean, Clinical Affairs, Emory University School of Medicine
  • Jonathan Kaufman, MD
    Associate Professor, Department of Hematology and Medical Oncology
  • Fadlo R. Khuri, MD, FACP
    Adjunct Professor of Hematology and Medical Oncology, Emory University
    President and Professor of Internal Medicine, American University of Beirut
  • Ragini Kudchadkar, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Amelia Langston, MD
    Professor and Executive Vice Chair, Hematology and Medical Oncology
    Director and Section Chief, Bone Marrow Transplant Program
  • David Lawson, MD
    Professor, Department of Hematology and Medical Oncology
    Co-Chair, Emory Melanoma and Pigmented Lesion Center
  • Mary Jo Lechowicz, MD
    Associate Professor and Vice Chair for Education, Department of Hematology and Medical Oncology
    Margaret H. Rollins Chair in Cancer
  • Michael Lowe, MD, MA
    Assistant Professor, Division of Surgical Oncology, Department of Surgery
  • Jane Meisel, MD
    Assistant Professor of Medicine, Department of Hematology and Medical Oncology
  • Ajay K. Nooka, MD, MPH, FACP
    Assistant Professor, Division of Bone Marrow Transplant
  • Jeffrey Olson, MD
    Professor, Departments of Hematology, Medical Oncology, and Neurosurgery
  • Taofeek Owonikoko, MD, PhD
    Associate Professor, Department of Hematology and Medical Oncology
  • Elsa Paplomata, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Mihir Patel, MD
    Assistant Professor, Department of Otolaryngology
  • Pretesh Patel, MD
    Assistant Professor, Department of Radiation Oncology
  • Rathi Pillai, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Maria C. Russell, MD
    Assistant Professor, Division of Surgical Oncology, Department of Surgery
  • Nabil Saba, MD, FACP
    Professor, Department of Hematology and Medical Oncology
    Director of Head and Neck Medical Oncology Program
  • Conor Steuer, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Preeti Subhedar, MD, MSPT
    Assistant Professor, Division of Surgical Oncology, Department of Surgery
  • Mylin Torres, MD
    Associate Professor, Department of Radiation Oncology
    Director, Glenn Family Breast Center
  • Edmund K. Waller, MD, PhD, FACP
    Professor, Departments of Medicine, Pathology, and Hematology and Medical Oncology
    Director of Stem Cell and Immune Therapy Division
    Director, Bone Marrow and Stem Cell Transplant Program
    Medical Director for the Center for Apheresis and the Stem Cell Processing Laboratory
  • Elliott Winton, MD
    Professor, Department of Hematology and Medical Oncology
  • Christina Wu, MD
    Associate Professor, Department of Hematology and Medical Oncology
  • Melinda Yushak, MD, MPH
    Assistant Professor, Department of Hematology and Medical Oncology

Thursday, July 27

Lung Cancer/Head and Neck Cancer/Lymphoma

  • 07.30 AM Strategies for enhancing the efficacy of immunotherapy
    Edmund Waller MD, PhD
  • 07.55 AM Debate 1—Are treatments for small cell lung cancer getting better?
    Yes: Rathi Pillai, MD
    No: Taofeek Owonikoko, MD, PhD, MSCR
  • 08.20 AM Targeted treatment for lung cancer: EGFR, ALK, and beyond
    Fadlo Khuri, MD
  • 08.45 AM Incorporating immunotherapy into the treatment of non-small cell lung cancer (NSCLC)
    Suresh Ramalingam, MD
  • 09.10 AM Combined modality therapy for stage 3 NSCLC
    Walter J. Curran, Jr, MD
  • 09.35 AM Management strategies for lung cancer sensitive or resistant to EGFR inhibitors
    Conor Steuer, MD
  • 10.00 AM BREAK
  • 10.20 AM Debate 2—Surgery is needed in the treatment of early-stage, human papillomavirus (HPV)-related oropharyngeal cancer
    No: Jonathan Beitler, MD, MBA, FACR, FASTRO
    Yes: Mihir Patel, MD
  • 10.45 AM Immunotherapy and new targets for head and neck cancer
    Nabil Saba, MD, FACP
  • 11.10 AM Novel therapeutic approaches for saliva gland cancers
    Conor Steuer, MD
  • 11.35 AM Debate 3—Have we moved beyond EPOCH for B-cell non-Hodgkin lymphoma?
    Yes: Christopher Flowers, MD, MS
    No: Jonathan Cohen, MD, MS
  • 12.00 PM Sorting through the options in relapsed follicular non-Hodgkin lymphoma (NHL)
    James Armitage, MD
  • 12.25 PM Lunch
  • 12.55 PM T-cell lymphomas: Diagnosis and new agents
    Mary Jo Lechowicz, MD
  • 1.20 PM Sequencing treatments in relapsed Hodgkin lymphoma
    Leonard Heffner, Jr, MD
  • 1.45 PM Complications in bone marrow transplant: GVHD, VOD, and beyond
    William Blum, MD
  • 2.10 PM MOC
  • 2.30 PM Adjourn

Friday, July 28

Gastrointestinal Cancers/Multiple Myeloma/Leukemia

  • 07.15 AM MOC
  • 07.30 AM Debate 1—Role of radiation in resectable and locally advanced pancreatic cancer?
    Yes: Pretesh Patel, MD
    No: Bassel El-Rayes, MD
  • 07.55 AM Immunotherapy in gastrointestinal (GI) malignancies
    Olatunji Alese, MD
  • 08.20 AM Colon cancer: Does side matter?
    Christina Wu, MD
  • 08.45 AM New strategies in the management of hepatocellular carcinoma
    Maria C. Russell, MD
  • 09.10 AM Updates and best practices in the management of gastric cancer
    Olatunji Alese, MD
  • 09.35 AM Debate 2—Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles
    Yes: Bassel El-Rayes, MD
    No: Christina Wu, MD
  • 10.00 AM BREAK
  • 10.20 AM A focus on marginal zone lymphoma: Current and future strategies
    Jonathon Cohen, MD
  • 10.45 AM Debate 3—Antibodies are a standard part of first relapse management in multiple myeloma (MM)
    Yes: Ajay Nooka, MD, MPH, FACP
    No: Jonathan Kaufman, MD
  • 11.10 AM New targets and treatments for relapsed MM
    Kenneth Anderson, MD
  • 11.35 AM Induction therapy and transplant for MM
    Sagar Lonial, MD
  • 12.00 PM The value in myeloid mutation panels in patients with myeloproliferative neoplasm (MPN)
    Elliot Winton, MD
  • 12.25 PM Lunch
  • 12.55 PM Debate 4—All fit patients with acute myeloid leukemia (AML) should receive 7+3 as induction
    No: Hagop Kantarjian, MD
    Yes: Martha Arellano, MD
  • 1.20 PM New concepts in the management of elderly patients with AML
    Martha Arellano, MD
  • 1.45 PM Amyloidosis, what to do and how to diagnosis
    Jonathan Kaufman, MD
  • 2.10 PM Chronic myeloid leukemia: What to do, when to do it, and when to stop
  • 2.35 PM MOC
  • 3.00 PM Adjourn

Saturday, July 29

Breast Cancer/Melanoma/Other Hematology Topics

  • 07.30 AM Debate 1—Is complete axillary dissection needed following mastectomy and sentinel node biopsy?
    Yes: Mylin Torres, MD
    No: Preeti Subhedar, MD, MSPT
  • 07.55 AM Role of molecular testing in tumor and blood for metastatic breast cancer
    Jane Meisel, MD
  • 08.20 AM Overcoming resistance to endocrine or HER2-directed therapy
    Jane Meisel, MD
  • 08.45 AM Triple-negative breast cancer: Subtyping and clinical implications
    Keerthi Gogineni, MSHP
  • 09.10 AM Management of metastatic hormone receptor–positive breast cancer
    Elsavet Paplomata, MD
  • 09.55 AM Debate 2—Does complete node dissection for sentinel lymph node (SNL)–positive melanoma have a role?
    Yes: David Lawson, MD
    No: Michael Lowe, MD, MA
  • 10.20 AM Immunotherapy for advanced melanoma: What and when?
    Ragini Kudchadkar, MD
  • 10.45 AM Genomics and melanoma: Who to test and what to test for
    Melinda Yushak, MD, MPH
  • 11.10 AM Immune and other new targets for brain tumors
    Jeffrey J. Olson, MD
  • 11.35 AM New approaches for sarcoma management
    Melinda Yushak, MD, MPH
  • 12.00 PM Lunch
  • 12.30 PM New treatments and combinations for relapsed chronic lymphocytic leukemia (CLL)
    Susan O’Brien, MD
  • 12.55 PM Debate 3—Allogeneic transplant should be used as salvage therapy for relapsed diffuse large B-cell lymphoma (DLBCL)
    Yes: Amelia Langston, MD
    No: Jonathon Cohen, MD
  • 1.20 PM How to choose and manages direct oral anticoagulants (DOACs)
    Ana Antun, MD
  • 1.45 PM Role and benefit of phase 1 trials, the Winship experience
    R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
  • 2.10 PM MOC
  • 2.30 PM Adjourn

Sunday, July 30

Genitourinary Cancers/Other Tumor Types

  • 07.15 AM Embarking on a thrombophilia workup: Who, what, and when
    Manila Gaddh, MD
  • 07.30 AM Debate 1—Adjuvant tyrosine kinase inhibitor (TKI) should be given for high-risk renal cell carcinoma (RCC) after nephrectomy
    Yes: Viraj Master, MD, PhD, FACS
    No: Mehmet Asim Bilen, MD
  • 07.55 AM Immune therapy and bladder cancer
    Bradley Carthon, MD, PhD
  • 08.20 AM Sequencing hormonal therapy and chemotherapy in prostate cancer
    Mehmet Asim Bilen, MD
  • 08.45 AM Targeted therapy for RCC
    Michael Atkins, MD
  • 09.10 AM The evolving role of PARP inhibition in the management of ovarian cancer
    Ira Horowitz, MD, SM, FACOG, FACS
  • 09.35 AM Management of thyroid malignancies
    Taofeek Owonikoko, MD, PhD, MSCR
  • 10.00 AM MOC
  • 10.25 AM Adjourn

Exhibitor Package

The exhibit fee will allow one 6’ exhibit table and complimentary registration, including meals, for two company representatives for all four days of the conference. Additional company representatives may register separately. Exhibit set up will be on Wednesday evening and should remain in place for the duration of the meeting. Attendees will have the opportunity to visit the exhibits during breakfast each morning, at the morning breaks, and before and after the lunch session.


Standard Exhibit Fee: $5000
Premier Placement Exhibit Fee: $7500
Additional representatives may attend for $800 a person ($1000 after April 21)

Registration

Online registration is available at www.winshipcancerDDHO.com. The name and email addresses of both representatives attending are required fields. Payment can be made by check or online by credit card.


PLEASE NOTE: If you choose to pay online via credit card, you will incur a 4.95% processing fee.


For payment by check, please make checks payable to prIME Oncology, LLC
Tax ID # 20-5392799 for the designated amount and send by overnight mail to:

prIME Oncology
5901 Peachtree Dunwoody Rd
Building C, Suite 250
Atlanta, GA 30328
Attention: Lisa Willey - DDHO


Download Forms

Please download the necessary forms, complete them, and return to Lisa Willey by email at Lisa.Willey@prIMEoncology.org or by fax at 678.892.1363.


Exhibit Request Letter
LOA – Premier Exhibit
LOA – Standard Exhibit
prIME LLC W-9